Is the TCH-P regimen active in early or locally advanced HER2-positive breast cancer? Results of a retrospective study

被引：0

作者：

Longo, Raffaele ^{[1
]}

Thiebaut, Victoire ^{[1
]}

Legros, Pierre-Olivier ^{[1
]}

Campitiello, Marco ^{[1
]}

Plastino, Francesca ^{[1
]}

Goetz, Christophe ^{[2
]}

Margineanu, Bogdan ^{[3
]}

Pujois, Julie ^{[3
]}

Gunther, Michel ^{[3
]}

Egea, Julie ^{[1
]}

Wendel, Chloe ^{[1
]}

机构：

[1] CHR Metz Thionville, Div Med Oncol, 1 Allee Chateau, F-57085 Ars Laquenexy, France

[2] CHR Metz Thionville, Clin Res Support Unit, Ars Laquenexy, France

[3] CHR Metz Thionville, Div Gynecol, Ars Laquenexy, France

来源：

ACTA ONCOLOGICA | 2022年 / 61卷 / 11期

关键词：

OPEN-LABEL; PLUS TRASTUZUMAB; LAPATINIB; SAFETY; CHEMOTHERAPY; EFFICACY; RECOMMENDATIONS; MULTICENTER; PERTUZUMAB; THERAPY;

D O I：

10.1080/0284186X.2022.2132115

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1394 / 1399

页数：6

共 50 条

[41] Treatment-induced amenorrhoea for patients with HER2-positive early breast cancer: does it matter? [J].

Gullo, Giuseppe ;

Gleeson, Jack P. .

TRANSLATIONAL CANCER RESEARCH, 2018, 7 (06) :1357-1360

[42] In the Middle of Life Give more Time to young Patients with early HER2-positive Breast Cancer [J].

Fessler, Beate .

BREAST CARE, 2021, 16 (03)

[43] Neoadjuvant pyrotinib plus trastuzumab and vinorelbine for HER2-positive locally advanced breast cancer patient who was initially resistant to HP therapy: a case report and literature review [J].

Liu, Mei ;

Zhou, Xin .

GLAND SURGERY, 2023, 12 (02) :317-323

[44] Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer [J].

Verma, Sunil ;

Miles, David ;

Gianni, Luca ;

Krop, Ian E. ;

Welslau, Manfred ;

Baselga, Jose ;

Pegram, Mark ;

Oh, Do-Youn ;

Dieras, Veronique ;

Guardino, Ellie ;

Fang, Liang ;

Lu, Michael W. ;

Olsen, Steven ;

Blackwell, Kim .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19) :1783-1791

[45] Pertuzumab in HER2-positive breast cancer [J].

Sendur, Mehmet A. N. ;

Aksoy, Sercan ;

Altundag, Kadri .

CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (10) :1709-1716

[46] Treatment of HER2-positive breast cancer [J].

Figueroa-Magalhaes, Maria Cristina ;

Jelovac, Danijela ;

Connolly, Roisin M. ;

Wolff, Antonio C. .

BREAST, 2014, 23 (02) :128-136

[47] Pyrotinib for HER2-positive metastatic breast cancer: a systematic review and meta-analysis [J].

Hu, Wenyu ;

Yang, Jixin ;

Zhang, Ze ;

Xu, Dongdong ;

Li, Nanlin .

TRANSLATIONAL CANCER RESEARCH, 2023, 12 (02) :247-+

[48] Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer [J].

Heo, Young-A ;

Syed, Yahiya Y. .

TARGETED ONCOLOGY, 2019, 14 (06) :749-758

[49] Pertuzumab: A New Targeted Therapy for HER2-Positive Metastatic Breast Cancer [J].

Malenfant, Stephanie J. ;

Eckmann, Karen R. ;

Barnett, Chad M. .

PHARMACOTHERAPY, 2014, 34 (01) :60-71

[50] Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results [J].

Bundred, Nigel ;

Porta, Nuria ;

Brunt, Adrian Murray ;

Cramer, Angela ;

Hanby, Andrew ;

Shaaban, Abeer M. ;

Rakha, Emad A. ;

Armstrong, Anne ;

Cutress, Ramsey, I ;

Dodwell, David ;

Emson, Marie A. ;

Evans, Abigail ;

Hartup, Sue M. ;

Horgan, Kieran ;

Miller, Sarah E. ;

McIntosh, Stuart A. ;

Morden, James P. ;

Naik, Jay ;

Narayanan, Sankaran ;

Ooi, Jane ;

Skene, Anthony, I ;

Cameron, David A. ;

Bliss, Judith M. .

CLINICAL CANCER RESEARCH, 2022, 28 (07) :1323-1334

← 1 2 3 4 5 →